These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9147417)

  • 1. The development of resistance of HIV-1 to zalcitabine.
    Craig C; Moyle G
    AIDS; 1997 Mar; 11(3):271-9. PubMed ID: 9147417
    [No Abstract]   [Full Text] [Related]  

  • 2. [Nucleoside analogs inhibiting reverse transcriptase: use in adult patient with HIV infection].
    Aguirrebengoa K; Mallolas J; Uriz J; Torres Tortosa M
    Enferm Infecc Microbiol Clin; 1996 Oct; 14 Suppl 1():3-9. PubMed ID: 9053024
    [No Abstract]   [Full Text] [Related]  

  • 3. Elvucitabine data released at CROI.
    AIDS Patient Care STDS; 2010 Mar; 24(3):198. PubMed ID: 20235383
    [No Abstract]   [Full Text] [Related]  

  • 4. Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs.
    de Jong JJ; Goudsmit J; Lukashov VV; Hillebrand ME; Baan E; Huismans R; Danner SA; ten Veen JH; de Wolf F; Jurriaans S
    AIDS; 1999 Jan; 13(1):75-80. PubMed ID: 10207547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
    Miller V; Stürmer M; Staszewski S; Gröschel B; Hertogs K; de Béthune MP; Pauwels R; Harrigan PR; Bloor S; Kemp SD; Larder BA
    AIDS; 1998 May; 12(7):705-12. PubMed ID: 9619801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differing reverse transcriptase mutation patterns in individuals experiencing viral rebound on first-line regimens with stavudine/didanosine and stavudine/lamivudine.
    Moyle GJ; Gazzard BG
    AIDS; 2001 Apr; 15(6):799-800. PubMed ID: 11371696
    [No Abstract]   [Full Text] [Related]  

  • 7. Drugs for HIV infection.
    Med Lett Drugs Ther; 2000 Jan; 42(1069):1-6. PubMed ID: 10683666
    [No Abstract]   [Full Text] [Related]  

  • 8. Human immunodeficiency virus 1 strains resistant to nucleoside inhibitors of reverse transcriptase in isolates from the Czech Republic as monitored by line probe assay and nucleotide sequencing.
    Reinis M; Vandasová J; Stanková M; Linka M; Brůcková M
    Acta Virol; 2001; 45(5-6):279-86. PubMed ID: 12083326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural Insights into HIV Reverse Transcriptase Mutations Q151M and Q151M Complex That Confer Multinucleoside Drug Resistance.
    Das K; Martinez SE; Arnold E
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28396546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reverse transcriptase fidelity and HIV-1 variation.
    Balzarini J; Pelemans H; De Clercq E; Karlsson A; Kleim JP
    Science; 1997 Jan; 275(5297):229-30; author reply 230-1. PubMed ID: 8999551
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment interruption after one year of triple nucleoside analogue therapy for primary HIV infection.
    Girard PM; Schneider V; Dehée A; Mariot P; Jacomet C; Delphin N; Damond F; Carcelain G; Autran B; Saimot AG; Nicolas JC; Rozenbaum W
    AIDS; 2001 Jan; 15(2):275-7. PubMed ID: 11216939
    [No Abstract]   [Full Text] [Related]  

  • 12. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
    AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guide to major clinical trials of antiretroviral therapy administered to patients infected with human immunodeficiency virus.
    Spooner KM; Lane HC; Masur H
    Clin Infect Dis; 1996 Jul; 23(1):15-27. PubMed ID: 8816123
    [No Abstract]   [Full Text] [Related]  

  • 14. Drugs for HIV infection.
    Med Lett Drugs Ther; 1997 Dec; 39(1015):111-6. PubMed ID: 9402928
    [No Abstract]   [Full Text] [Related]  

  • 15. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee.
    Brun-Vézinet F; Boucher C; Loveday C; Descamps D; Fauveau V; Izopet J; Jeffries D; Kaye S; Krzyanowski C; Nunn A; Schuurman R; Seigneurin JM; Tamalet C; Tedder R; Weber J; Weverling GJ
    Lancet; 1997 Oct; 350(9083):983-90. PubMed ID: 9329513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
    Albrecht MA; Hughes MD; Liou SH; Katzenstein DA; Murphy R; Balfour HH; Para MF; Valdez H; Hammer SM;
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1337-44. PubMed ID: 11018853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy.
    Kavlick MF; Wyvill K; Yarchoan R; Mitsuya H
    J Infect Dis; 1998 Jun; 177(6):1506-13. PubMed ID: 9607827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel genotype encoding a single amino acid insertion and five other substitutions between residues 64 and 74 of the HIV-1 reverse transcriptase confers high-level cross-resistance to nucleoside reverse transcriptase inhibitors. Abacavir CNA2007 International Study Group.
    Rakik A; Ait-Khaled M; Griffin P; Thomas TA; Tisdale M; Kleim JP
    J Acquir Immune Defic Syndr; 1999 Oct; 22(2):139-45. PubMed ID: 10843527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.
    Sirivichayakul S; Ruxrungtham K; Ungsedhapand C; Techasathit W; Ubolyam S; Chuenyam T; Emery S; Cooper D; Lange J; Phanuphak P
    AIDS; 2003 Sep; 17(13):1889-96. PubMed ID: 12960821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.
    van der Hoek L; Back N; Jebbink MF; de Ronde A; Bakker M; Jurriaans S; Reiss P; Parkin N; Berkhout B
    J Virol; 2005 Mar; 79(6):3536-43. PubMed ID: 15731248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.